

**Institute of Primate Research**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SOP No.** | **Issue Number** | **Issue Date** | **Revision Status** | **Revision Date** |
| **SOP/KIPRE/RPD/DSAS/3.1.76** | **Version 01** | **October 2025** | **-** | **-** |

**STANDARD OPERATING PROCEDURE (SOP) DOCUMENT**

**Evaluating disease control programs (epidemiological and cost-effectiveness frameworks)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Approvals** |  |  |  |
|  | **Name** | **Signature** | **Date** |
| **Developed by:** | \_Patrick Waweru Mwaura\_ | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_6th October; 2025\_** |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** |
| **Reviewed by:** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** |
| **Approved by:** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** | **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_** |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |

**Table of Contents**

[1. PURPOSE 4](#_Toc144316958)

[2. SCOPE 4](#_Toc144316959)

[3. PERSONS RESPONSIBLE: 4](#_Toc144316960)

[4. FREQUENCY 4](#_Toc144316961)

[5. MATERIALS 4](#_Toc144316962)

[6. PROCEDURE 4](#_Toc144316963)

[7. REFERENCES 5](#_Toc144316964)

# 

# PURPOSE

To establish a rigorous and standardized approach for evaluating disease control programs, using epidemiological models and cost-effectiveness frameworks to guide public health decision-making.

# SCOPE

Applies to all disease control interventions assessed by DS&AS, including pre-clinical trials, community surveillance studies, and One Health programs.

# PERSONS RESPONSIBLE

* **Epidemiologist (DS&AS):** Leads design and execution of program evaluations.
* **Health Economist / Biostatistician:** Conducts cost-effectiveness and impact analyses.
* **Head of DS&AS:** Approves methodology and reports.
* **PI / Programme Lead:** Provides program-specific details and data access.

# FREQUENCY

* **At program milestones** (baseline, midline, end line).
* **Ad-hoc evaluations** when significant policy or funding decisions are required.

# MATERIALS

* Epidemiological models (survival analysis, transmission dynamics, and regression frameworks).
* Cost-effectiveness analysis (CEA) templates.
* Health outcome measures (DALYs, QALYs, incidence reduction).
* National and institutional health program evaluation guidelines.

# PROCEDURE

1. **Planning:** Define evaluation objectives, target population, and intervention.
2. **Data Collection:** Gather surveillance, program, and cost data.
3. **Epidemiological Analysis:** Apply statistical and modelling methods to assess program impact on incidence, prevalence, or survival.
4. **Cost-Effectiveness Analysis:** Estimate incremental cost-effectiveness ratios (ICERs) based on costs per DALY/QALY averted.
5. **Validation:** Peer review methodology internally within DS&AS.
6. **Reporting:** Compile findings into dashboards, reports, and policy briefs.
7. **Dissemination:** Share with institutional leadership, policymakers, and stakeholders.

# REFERENCES